RxDoctor Payments Data

Adrienne Fortner, APRN

Family · Stanton, KYNPI 1972151769

Payments from drug & device makers

$8,277in general payments, 2019–2025

Across 400 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$769
  • GSK$747
  • Pfizer$686
  • Bayer$541
  • Novo Nordisk$417
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$8,277100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,277 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$50,927
Medicare patients
187
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$39,475
MounjaroTirzepatide34$35,507
JardianceEmpagliflozin14$17,747
LinzessLinaclotide12$16,475
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,280
Albuterol Sulfate HfaAlbuterol Sulfate43$1,174
Celecoxib22$983
Atorvastatin Calcium117$882
Estradiol11$801
Gabapentin56$753
Diclofenac Sodium19$705
Hydroxyzine Hcl41$636
Levothyroxine Sodium73$625
Lidocaine Hcl ViscousLidocaine Hcl24$591
Nystatin27$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$417$39,47527 claims
Lilly USA, LLCMounjaro$769$35,50734 claims
Boehringer IngelheimJardiance$168$17,74714 claims
AbbVieLinzess$1,880$16,47512 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$62573 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Stanton

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →